AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00493246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Acetaminophen
Description: This study will investigate two doses (12.5 milligrams/kilogram (mg/kg) and 15 milligrams/kilogram) based on weight administered every four hours (q4h), every six hours (q6h), or every eight hours (q8h) (depending on age)~Neonates: 12.5 mg/kg q6h IV acetaminophen Neonates: 15 mg/kg q8h IV acetaminophen Infants: 12.5 mg/kg q4h IV acetaminophen Infants: 15 mg/kg q6h IV acetaminophen Children: 12.5 mg/kg q4h IV acetaminophen Children: 15 mg/kg q6h IV acetaminophen Adolescents: 12.5 mg/kg q4h IV acetaminophen Adolescents: 15 mg/kg q6h IV acetaminophen
Study NCT04223999 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skullremodeling surgery
Description: Strategically placed cranial burrholes in order to improve the TTField dose focally in the tumor.
Study NCT01560416 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Study NCT01560416 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ganetespib
Study NCT00407082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluocinolone acetonide intravitreal implant
Description: Fluocinolone acetonide ocular implant 0.59mg
Study NCT00407082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluocinolone acetonide 2.1mg
Description: Fluocinolone acetonide ocular implant 2.1mg
Study NCT02342210 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mindfulness Ambassador Council for Early Psychosis (MAC-EP)
Description: MAC is a 12-week facilitated group mindfulness intervention promoting the development of social-emotional competence in youth created by Mindfulness Without Borders (MWB; www.mwb.org). A meditative practice, mindfulness focuses one's awareness on the present, acknowledging and accepting without judging one's feelings, thoughts, or bodily sensations. Each session has a unique focus (e.g., paying attention, practicing gratitude) and consists of facilitated group learning, discussion and mindfulness skills practice. Home assignments to help reinforce specific lesson are also assigned. Although MAC has demonstrated acceptability, feasibility, and promising beneficial effects in schools, it has yet to be implemented and/or evaluated in a clinical population. Its youth-focus and emphasis on building social and emotional competencies through mindfulness, in addition to teaching core mindfulness skills make it a promising intervention for youth recovering from their first episode of psychosis.
Study NCT02909439 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: Sugammadex will be given for reversal of neuromuscular blockade.
Study NCT02909439 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: Neostigmine will be given for reversal of neuromuscular blockade.
Study NCT00318019 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: OPC Factor(TM)
Description: Evervescent poweder containing oligomeric proanthocyanidins (OPCs)and other nutrients.
Study NCT00318019 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Effervescent powder similar in taste and appearance to the intervention but without the OPCs and nutrients.
Study NCT03284905 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic supplement
Description: Capsule containing freeze dried probiotic bacteria together with maize starch
Study NCT00681967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: 250 mg; oral
Study NCT00681967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: 250mg; oral
Study NCT02913352 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Latarjet procedure
Description: Open anterior glenoid bone graft from coracoid process
Study NCT02913352 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified Eden-Hybinette
Description: Open anterior glenoid bone graft from iliac bone crest, with capsular suture and screw fixation
Study NCT02074306 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UROSHIELD®
Description: An active UROSHIELD® device (low energy acustic wave generator) will be connected to an intratracheal tube externally. The device will transform low energy ultrasound waves on to the tube. These waves will by assumption lower the formation of bacterial growth and resistance to antibiotics.
Study NCT02074306 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM UROSHIELD®
Description: SHAM UROSHIELD® will be connected to endotracheal tubes unable to transform any waves.
Study NCT01557218 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cucumber snack
Description: Three 300-g bowls of vegetables per table: three of cucumber slices
Study NCT01557218 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pepper snack
Description: Three 300-g bowls of vegetables per table: three of yellow pepper strips
Study NCT01557218 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tomato snack
Description: Three 300-g bowls of vegetables per table: three of grape tomatoes
Study NCT01557218 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vegetable variety snack
Description: Three 300-g bowls of vegetables per table: one each of cucumber slices, pepper strips, and grape tomatoes
Study NCT01557218 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Apple snack
Description: Three 300-g bowls of fruits per table: three of apple wedges
Study NCT01557218 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peach snack
Description: Three 300-g bowls of fruits per table: three of peach slices
Study NCT01557218 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pineapple snack
Description: Three 300-g bowls of fruits per table: three of pineapple half-rings
Study NCT01557218 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fruit variety snack
Description: Three 300-g bowls of fruits per table: of each of apple wedges, peach slices, and pineapple half-rings
Study NCT02176291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: low-dose buprenorphine (range 0.2 mg/day -- 2.0 mg/day)
Study NCT02176291 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matched placebo
Study NCT03978624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg IV on day 1 and day 22
Study NCT04223999 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Tumor treating fields combined with best medical treatment.
Study NCT03144817 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dialysate Sodium Lowering
Description: Dialysate sodium is lowered until nadir sodium level is reached. Participant dialyzes at this sodium level until end of follow-up.
Study NCT01000610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab [MabThera/Rituxan]
Description: 1000 mg iv infusion on days 1 and 15
Study NCT01000610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: 10-25 mg weekly (oral or parenteral)
Study NCT01000610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: 100 mg iv prior to each rituximab infusion
Study NCT03978624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat
Description: 5 mg given orally on day 1, day 8 and day 15
Study NCT02723110 — intervention group
Intervention type: OTHER
Intervention: 4 Hour Frequently Sampled Oral Glucose Tolerance Test
Description: Blood glucose level(BGL) every 5 min, blood for hormone, biochemical analysis at -15,0,15,30,45,60,90,120,180, 240
Study NCT02723110 — intervention group
Intervention type: OTHER
Intervention: Isoglycaemic Clamp
Description: Glucose infusion over 4 hours to reproduce OGTT glucose curve to allow measurement of incretin effect. BGL every 5 min, blood for hormone, biochemical analysis at -15,0,15,30,45,60,90,120,180, 240
Study NCT04674618 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: US-assisted nusinersen administration
Description: Ultrasound identification of intervertebral space (L2-L3 or L3-L4)
Study NCT04202653 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ETV
Description: entecavir 0.5 mg qd
Study NCT04202653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETV
Description: entecavir 0.5 mg qd
Study NCT04202653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQ-A3334
Description: TQ-A3334 po qw
Study NCT03873844 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speed of Processing Training
Description: Speed of Processing Training (SOPT). Speed of processing training involves trainer-guided practice of computer-based video games. The games require the player to identify targets that are presented very briefly. SOPT has the primary aim of improving the fluid ability of mental processing speed such that trainees can process increasingly more information and increasingly more complex information over briefer periods of time. The training primarily involves practice with feedback. Trainers also offer suggestions, encouragement, and personalized modifications of difficulty for the trainee according to a specified protocol. At a display speed and task difficulty level tailored to their ability, trainees practice blocks of 16 trials. Trainees receive immediate feedback after each trial and see their total correct trials at the end of each block of trials. Trainers tell the trainees that their goal is to achieve performance of 10 to 12 correct trials for each training block.
Study NCT04202653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQ-B2450
Description: TQ-B2450 q3w iv
Study NCT00643487 — intervention group
Intervention type: PROCEDURE
Intervention: observation of the behavior of the infrapatellar plica
Description: Local anesthesia using bupivicaine will be initiated. The IPP, if present will be injected with contrast material. In order to minimize discomfort, lidocaine 1%, in as small a volume as possible, will be injected into the fat pad under direct vision to avoid any intra-articular damage from the #25 needle. Radiographic visualization will be verified and the knee taken through a full range of passive and active exercises. Active quadriceps contraction in the subject will be performed at 0, 15, 30 60 and 90 degrees of flexion. In so far as is technically possible, the behavior of the IPP will be videotaped and recorded on lateral fluoroscopy.
Study NCT00755846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin 6.25 mg, tablets, orally, once daily for up to 12 weeks
Study NCT00755846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin 12.5 mg, tablets, orally, once daily for up to 12 weeks.
Study NCT00755846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin 25 mg, tablets, orally, once daily for up to 12 weeks.
Study NCT00755846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin 50 mg, tablets, orally, once daily for up to 12 weeks.
Study NCT00755846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin 100 mg, tablets, orally, once daily for up to 12 weeks.
Study NCT00755846 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Alogliptin placebo-matching tablets, orally, once daily for up to 12 weeks.
Study NCT03604510 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electroencephalographic recordings
Description: 24 hours of electroencephalographic recordings (EEG-Holter) of prefrontal activity of Tourette's syndrome (TS) patients in ecological conditions.
Study NCT02678663 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Injection-assisted Cold Snare Polypectomy
Description: Resection of a polyp after blue-tinted saline injection using a cold snare (without application of electrocautery)
Study NCT02678663 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic Mucosal Resection
Description: Resection of a polyp after blue-tinted saline injection using snare electrocautery
Study NCT03284905 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplement
Description: Capsule containing maize starch
Study NCT03095521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angal, lozenges [menthol],
Description: Angal, administered per 1 lozenge, with an interval 2 hours or more, 6-10 lozenges per day, for a maximum 4 days or until full illness resolution.
Study NCT03095521 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ANTI-ANGIN® FORMULA
Description: 0,2 mg + 2 mg + 50 mg (LLC Valeant, Russia). Administered per 1 lozenge, with an interval 2 hours or more, up to 6 lozenges per day, for a maximum 5 days or until full illness resolution.
Study NCT01496521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 100mg qd for 6 months.
Study NCT03414008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1291583
Description: Single dose
Study NCT03414008 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo: Tartaric acid
Description: Single dose
Study NCT00383721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate/formoterol (MF/F) combination
Description: MF/F 400/10 mcg via a metered dose inhaler (MDI) twice daily for 52 weeks
Study NCT00383721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate/formoterol (MF/F) combination
Description: MF/F 200/10 mcg via a metered dose inhaler (MDI) twice daily for 52 weeks
Study NCT00383721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate MDI (MF MDI)
Description: MF 400 mcg via metered dose inhaler twice daily for 52 weeks
Study NCT00383721 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol MDI
Description: Formoterol 10 mcg via metered dose inhaler twice a day for 52 weeks
Study NCT00383721 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo MDI twice a day for 26 weeks
Study NCT03076190 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducational My Surgical Success Video
Description: The 90-minute video includes instruction by Dr. Beth Darnall, PhD, a pain psychologist at the Stanford Pain Management Center. She teaches the viewer about the relationship between stress, pain, and catastrophizing and provides instruction and skills to reduce catastrophizing, decrease stress, and increase relaxation.
Study NCT01496521 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tea Polyphenols
Description: 300mg bid for 6 months.
Study NCT04284904 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: aGVHD biomarker
Description: To verify the effectiveness of aGVHD biomarkers monitoring in predicting aGVHD risks
Study NCT00669916 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIN457
Description: single infusion of 3 mg/kg
Study NCT00669916 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single infusion of placebo
Study NCT00910429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat (Adempas, BAY63-2521)
Description: BAY63-2521 - 1 mg tid - 2,5 mg tid orally until end of study
Study NCT00723411 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rhGAD65
Description: Diamyd (rhGAD65) 20 µg injected subcutaneously at days 1, 30, 90 and 270.
Study NCT03873844 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transfer Package from CI Therapy
Description: Behavioral Contract. At the outset of treatment, the therapist negotiates a contract with the participant and caregiver, if one is available.Daily home diary. During treatment, the participants catalog the ADL and IADL for the part of the day spent outside the laboratory. Daily administration of the Cognitive Task Activity Log (CTAL). The CTAL collects information about attempts by the participant to complete ADL and IADL. Problem Solving. The therapist helps participants to think through any barriers to completing ADL and IADL independently. Home skill assignments during treatment. Participants are assigned on a written check-off sheet 10 specific ADL tasks. Home skill assignments after treatment. Toward the end of treatment, a written individualized post-treatment program is developed containing a list of up to 10 IADL for each day of the week. Post-treatment telephone contacts. Participants are contacted during the 12 month period after treatment to evaluate treatment outcomes.
Study NCT04299074 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: addiction
Description: questionnaire
Study NCT00723411 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rhGAD65
Description: Diamyd (rhGAD65) 20 µg injected subcutaneously at days 1 and 30, followed by placebo injections at days 90 and 270.
Study NCT00723411 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo injected subcutaneously at days 1, 30, 90 and 270
Study NCT01666691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beloranib
Description: Subjects will receive ZGN-440 twice-weekly subcutaneous injections for up to 12 weeks and a total of 24 doses. A range of doses will be evaluated.
Study NCT01666691 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive placebo twice-weekly subcutaneous injections for up to 12 weeks and a total of 24 doses.
Study NCT02260466 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: a basal LV septum biopsy
Description: During surgery, a basal LV septum biopsy will be collected for determination and quantification of interstitial deposits using specific staining which will be performed in a blind fashion
Study NCT02399592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10 mg/kg q3w
Study NCT02399592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocotrinol
Description: 300 mg tid
Study NCT01693133 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care: Moist Wound Therapy and Offloading
Description: Standard of Care: Moist Wound Therapy and Offloading
Study NCT01693133 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EpiFix plus Standard of Care
Description: Weekly application of EpiFix and Standard of Care
Study NCT04417725 — intervention group
Intervention type: OTHER
Intervention: Not applicable - this is a non-interventional, observational study.
Description: Not applicable - this is a non-interventional, observational study.
Study NCT04212286 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Diagnostic CEUS and EOB-MRI
Description: Undergo Sonovue-CEUS and EOB-MRI
Study NCT06429878 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Biparametric prostatic MRI
Study NCT06429878 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Biparametric prostatic MRI
Study NCT00547638 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cyanoacrylate with pressure sensitive mesh
Description: Topical Skin Adhesive
Study NCT00547638 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cyanoacrylate
Description: Topical Skin Adhesive
Study NCT04110418 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylene Blue
Description: Methylene Blue group (Group MB):will receive IV MB initiated with a first loading dose ( 1 mg/kg over 30 minutes ) then continuous IV infusion( 0.15 mg/kg per hour for up to 24 hours)~Terlipressin Group (Group TP) Terlipressin will be initiated with a loading dose ( 2 μg/kg intravenous over 30 minutes ) followed by continuous IV infusion starting by 2 μg/kg/h escalating up every 15 minutes up to 20 μg/kg/h
Study NCT04110418 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylene Blue
Description: Methylene Blue group (Group MB):will receive IV MB initiated with a first loading dose ( 1 mg/kg over 30 minutes ) then continuous IV infusion( 0.15 mg/kg per hour for up to 24 hours)~Terlipressin Group (Group TP) Terlipressin will be initiated with a loading dose ( 2 μg/kg intravenous over 30 minutes ) followed by continuous IV infusion starting by 2 μg/kg/h escalating up every 15 minutes up to 20 μg/kg/h
Study NCT04557254 — intervention group
Intervention type: DEVICE
Intervention: graft
Description: evaluate the early and long-term clinical results, up to 5 years (through follow-up outpatient visits), of a silver and triclosan knitted collagen coated polyester vascular graft (InterGard Synergy), in patients submitted to aortic surgical repair, and compare them with concurrent results of standard Dacron grafts.
Study NCT01423773 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon A test contact lens
Description: Silicone hydrogel single vision, soft contact lens with alternate parameters
Study NCT01423773 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon A control contact lens
Description: Silicone hydrogel single vision, soft contact lens
Study NCT01423773 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Ultra-High Resolution Optical Coherence Tomographer (OCT)
Description: Investigational, nonsignificant risk device for measuring post lens clearance and ocular tissue compression during contact lens wear